H3 Biomedicine is an oncology drug discovery company.
General company ifno:
Year of founded: 2010
Zip Code: 02139
Employees: 51-200
In sector: Scientific Research
Revenue Sources: Lead generation to other businesses
Social Impact:
Description:
At H3 Biomedicine, drug discovery starts with the patient. With deep expertise in the genetics of cancer, we mine the large cache of publicly available cancer genomics data. Our scientists work outward from genetically defined populations to identify or to confirm therapeutic targets. Our discovery teams then apply the latest chemical synthesis and cell-based screening methods to rapidly classify and develop libraries of small molecules that interact with those targets. They also seek to develop biomarkers to facilitate patient identification and clinical testing. This disciplined method promises to produce a steady stream of novel anti-cancer compounds against targets that have not yet been “druggable.”
Financial Info:
H3 Biomedicine is a 100%-owned subsidiary of Eisai Corporation Limited based in Tokyo and receives research contract fees every year. we received approximately $ 50M for the fiscal year 2013 (April 2013 through March 2014).